Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Apr;21(4):443-51.
doi: 10.1592/phco.21.5.443.34490.

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

D S Streetman  1 , A N Nafziger, C J Destache, A S Bertino Jr
Affiliations

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

D S Streetman et al. Pharmacotherapy. 2001 Apr.

Abstract

Study objective: To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN).

Design: Retrospective case-control study.

Setting: Two teaching hospitals.

Subjects: Two thousand four hundred five patients who received aminoglycosides.

Intervention: Aminoglycoside therapy dosed by either IPM or physicians' directions.

Measurements and main results: Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9% vs 13.2%, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients.

Conclusion: Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.

PubMed Disclaimer

MeSH terms

LinkOut - more resources